MedTrace Logo

Effects of A Standardized Treatment Approach on Kidney Transplant Recipients With Antibody-Mediated Rejection

NCT04367610 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 75

Last updated 2021-05-18

No results posted yet for this study

Summary

Antibody-mediated rejection (ABMR) is one of the leading causes of graft loss in kidney transplant recipients (KTRs). Although it is a well characterized entity, there is limited data regarding effective treatment options for preserving graft functions. Moreover, results from different studies have been contradictory. Therefore, we conducted a study using our registry data to evaluate the effects of a standardized treatment approach consisting of therapeutic plasma exchange (regular plasmapheresis, double filtration plasmapheresis or immunoadsorption), intravenous immunoglobulin and rituximab on KTRs with acute or chronic ABMR.

Conditions

  • Antibody-mediated Rejection
  • Kidney Transplant Rejection
  • Graft Loss

Sponsors & Collaborators

  • Istanbul University

    lead OTHER

Principal Investigators

  • Halil Yazici, MD · Department of Internal Medicine, Istanbul Faculty of Medicine

  • Safak Mirioglu, MD · Department of Internal Medicine, Istanbul Faculty of Medicine

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-01
Primary Completion
2020-08-31
Completion
2020-12-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04367610 on ClinicalTrials.gov